Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth hormone replacement in adult childhood cancer survivors with growth hormone deficiency
NL-OMON33094Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- Oct 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of somatropin in growth hormone deficiency (GHD), sponsored by Novo Nordisk. Primary endpoints: Change in visceral organ size, Change in renal function and 1 more. Planned start Oct 2009; status: not yet recruiting.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NL-OMON33094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33094.